Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes

 
• By Sten Stovall
  
Factor VIII
Novo Nordisk CSO Comments Come As FDA Approves Long-Acting Factor VIII replacement therapy Esperoct • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip